Mortality in Western Australian seniors with chronic respiratory diseases: a cohort study

Abstract

BackgroundRelatively few studies have examined survival by pharmacotherapy level and the effects of patient characteristics on mortality by pharmacotherapy level in older chronic respiratory disease (CRD) patients. This study aimed to investigate these issues in older (≥ 65) CRD patients in Western Australia.MethodsWe identified 108,312 patients ≥ 65 years with CRD during 1992-2006 using linked medical, pharmaceutical, hospital and mortality databases held by the Commonwealth and State governments. Pharmacotherapy classification levels were designed by a clinical consensus panel. Cox regression was used to investigate the study aim.ResultsPatients using only short acting bronchodilators experienced similar, but slightly worse survival than patients in the highest pharmacotherapy level group using high dose inhaled corticosteroids (ICS) ± long acting bronchodilators (LABs) ± oral steroids. Patients using low to medium dose ICS ± LABs experienced relatively better survival. Also, male gender was associated with all-cause mortality in all patients (HR = 1.72, 95% CI 1.65-1.80) and especially in those in the highest pharmacotherapy level group (HR = 1.97, 95%CI = 1.84-2.10). The P-value of interaction between gender and pharmacotherapy level for the effect on all-cause death was significant (0.0003).ConclusionsOlder patients with CRD not using ICS experienced the worst survival in this study and may benefit from an escalation in therapeutic regime. Males had a higher risk of death than females, which was more pronounced in the highest pharmacotherapy level group. Hence, primary health care should more actively direct disease management to mild-to-moderate disease patients.

Ankle-brachial index and the incidence of cardiovascular events in the Mediterranean low cardiovascular risk population ARTPER cohort

“…Baseline prevalence of PAD and AC was 7.6% and 6.2% respectively [4]. 479 members of the ARTPER cohort previously presented some cardiovascular event and therefore were excluded from the analysis of the study.…”

Comparison of medication adherence measures derived from linked administrative data and associations with mortality using restricted cubic splines in heart failure patients

“…We identified a cohort of 4234 patients, aged 65 to 84 years, with an index (first in period) hospitalization between 2003 and 2008 for HF as principal discharge diagnosis or HF as a secondary discharge diagnosis with ischaemic heart disease as principal discharge diagnosis and who survived 1 year (landmark period) following hospitalization for HF . Patients with a history of valvular heart disease or dialysis, nonconcession card holders, and those without any PBS records were excluded . The coding of HF admissions and myocardial infarction in administrative hospital morbidity data has been previously validated …”

Gathering data for decisions: best practice use of primary care electronic records for research

“…The first Australian primary care data linkage project started in Western Australia in 2007, when Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) data were linked to several state health care datasets. This enabled studies of the effects of primary care on hospitalisations and mortality for several chronic diseases . However, the limited clinical information within MBS and PBS datasets meant that assumptions had to be made to elicit meaning from the data.…”

“…Further, the ability to link different data sources together (eg, primary care and hospital data) also has enormous value. It can increase the range of questions that research can answer, improve statistical properties of data, and improve use of resources . Despite these benefits, the full potential of such data‐based research has not been realised.…”